Literature DB >> 7873134

Major depression, dysthymia and depressive personality disorder.

R M Hirschfeld1.   

Abstract

The separation of persistent depression into meaningful and useful subcategories, including major depression, dysthymia, recurrent brief depression, and depressive personality disorder, is the subject of much debate. Depressions can be grouped on the basis of their type and severity of symptoms, aetiology, clinical course, or their association with other psychiatric illnesses. Several investigators have conducted epidemiologic and family studies to evaluate the prevalence of depressive disorders, their diagnostic stability over time, and the amount of overlap among the disorders. Although progress has been made toward a better understanding of the different disorders, insufficient evidence exists to support the hypothesis that these disorders are separate and distinct from one another. However, preliminary data suggest that depressive personality disorder is separate from the other disorders. Additionally, several questions have been raised, particularly the extent to which differentiation between the depressive disorders, specifically major depression and dysthymia, has an impact on treatment decisions.

Entities:  

Mesh:

Year:  1994        PMID: 7873134

Source DB:  PubMed          Journal:  Br J Psychiatry Suppl        ISSN: 0960-5371


  3 in total

1.  Dimensions of the Typus melancholicus personality type.

Authors:  Klaus-Thomas Kronmüller; Matthias Backenstrass; Karen Kocherscheidt; Aoife Hunt; Peter Fiedler; Christoph Mundt
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2005-05-20       Impact factor: 5.270

Review 2.  Depression and associated physical diseases and symptoms.

Authors:  Guy M Goodwin
Journal:  Dialogues Clin Neurosci       Date:  2006       Impact factor: 5.986

3.  Nortriptyline versus fluoxetine in the treatment of major depressive disorder: a six-month, double-blind clinical trial.

Authors:  Sn Hashemi; Hr Ghafarian Shirazi; A Mohammadi; Gh Zadeh-Bagheri; Kh Noorian; M Malekzadeh
Journal:  Clin Pharmacol       Date:  2012-01-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.